CA3222159A1 - Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof - Google Patents
Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof Download PDFInfo
- Publication number
- CA3222159A1 CA3222159A1 CA3222159A CA3222159A CA3222159A1 CA 3222159 A1 CA3222159 A1 CA 3222159A1 CA 3222159 A CA3222159 A CA 3222159A CA 3222159 A CA3222159 A CA 3222159A CA 3222159 A1 CA3222159 A1 CA 3222159A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- sequence
- hao1
- nucleotide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197073P | 2021-06-04 | 2021-06-04 | |
| US63/197,073 | 2021-06-04 | ||
| US202163225046P | 2021-07-23 | 2021-07-23 | |
| US63/225,046 | 2021-07-23 | ||
| US202163292889P | 2021-12-22 | 2021-12-22 | |
| US63/292,889 | 2021-12-22 | ||
| US202263300727P | 2022-01-19 | 2022-01-19 | |
| US63/300,727 | 2022-01-19 | ||
| PCT/US2022/032144 WO2022256642A2 (en) | 2021-06-04 | 2022-06-03 | Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3222159A1 true CA3222159A1 (en) | 2022-12-08 |
Family
ID=82694238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3222159A Pending CA3222159A1 (en) | 2021-06-04 | 2022-06-03 | Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20230032141A1 (https=) |
| EP (1) | EP4347833A2 (https=) |
| JP (1) | JP2024520691A (https=) |
| KR (1) | KR20240034746A (https=) |
| AU (1) | AU2022283922A1 (https=) |
| CA (1) | CA3222159A1 (https=) |
| CO (1) | CO2023018656A2 (https=) |
| IL (1) | IL308803A (https=) |
| MX (1) | MX2023014406A (https=) |
| PH (1) | PH12023553297A1 (https=) |
| TW (1) | TW202317763A (https=) |
| WO (1) | WO2022256642A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4711451A1 (en) * | 2023-05-11 | 2026-03-18 | Yoltech Therapeutics Co., Ltd | Cas protein, corresponding gene editing system thereof and use thereof |
| WO2025147604A1 (en) | 2024-01-05 | 2025-07-10 | Arbor Biotechnologies, Inc. | Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3581654B1 (en) * | 2013-12-27 | 2021-03-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna |
| WO2019178427A1 (en) | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
| MX2021001070A (es) * | 2018-07-31 | 2021-05-27 | Intellia Therapeutics Inc | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1). |
| CN121380024A (zh) * | 2020-03-31 | 2026-01-23 | 阿伯生物技术公司 | 包含Cas12i2变体多肽的组合物及其用途 |
| WO2021257730A2 (en) * | 2020-06-16 | 2021-12-23 | Arbor Biotechnologies, Inc. | Cells modified by a cas12i polypeptide |
| CN113308451B (zh) * | 2020-12-07 | 2023-07-25 | 中国科学院动物研究所 | 工程化的Cas效应蛋白及其使用方法 |
-
2022
- 2022-06-03 IL IL308803A patent/IL308803A/en unknown
- 2022-06-03 MX MX2023014406A patent/MX2023014406A/es unknown
- 2022-06-03 WO PCT/US2022/032144 patent/WO2022256642A2/en not_active Ceased
- 2022-06-03 PH PH1/2023/553297A patent/PH12023553297A1/en unknown
- 2022-06-03 JP JP2023574534A patent/JP2024520691A/ja active Pending
- 2022-06-03 US US17/832,038 patent/US20230032141A1/en active Pending
- 2022-06-03 AU AU2022283922A patent/AU2022283922A1/en active Pending
- 2022-06-03 CA CA3222159A patent/CA3222159A1/en active Pending
- 2022-06-03 US US18/565,575 patent/US20240254494A1/en active Pending
- 2022-06-03 KR KR1020247000358A patent/KR20240034746A/ko active Pending
- 2022-06-03 EP EP22747156.2A patent/EP4347833A2/en active Pending
- 2022-06-06 TW TW111120922A patent/TW202317763A/zh unknown
- 2022-11-04 US US18/052,801 patent/US11821012B2/en active Active
-
2023
- 2023-12-29 CO CONC2023/0018656A patent/CO2023018656A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024520691A (ja) | 2024-05-24 |
| US20240254494A1 (en) | 2024-08-01 |
| AU2022283922A9 (en) | 2023-12-14 |
| WO2022256642A3 (en) | 2023-01-12 |
| US20230212541A1 (en) | 2023-07-06 |
| AU2022283922A1 (en) | 2023-12-07 |
| PH12023553297A1 (en) | 2024-03-18 |
| CO2023018656A2 (es) | 2024-01-25 |
| KR20240034746A (ko) | 2024-03-14 |
| IL308803A (en) | 2024-01-01 |
| TW202317763A (zh) | 2023-05-01 |
| WO2022256642A2 (en) | 2022-12-08 |
| EP4347833A2 (en) | 2024-04-10 |
| US20230032141A1 (en) | 2023-02-02 |
| MX2023014406A (es) | 2024-02-12 |
| US11821012B2 (en) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240261435A1 (en) | Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof | |
| US11821012B2 (en) | Gene editing systems comprising an RNA guide targeting hydroxyacid oxidase 1 (HAO1) and uses thereof | |
| US20250127924A1 (en) | Gene editing systems comprising an rna guide targeting stathmin 2 (stmn2) and uses thereof | |
| US20230399639A1 (en) | Compositions comprising an rna guide targeting b2m and uses thereof | |
| WO2023018856A1 (en) | Gene editing systems comprising an rna guide targeting polypyrimidine tract binding protein 1 (ptbp1) and uses thereof | |
| US11939607B2 (en) | Gene editing systems comprising an RNA guide targeting lactate dehydrogenase a (LDHA) and uses thereof | |
| US20230407343A1 (en) | Compositions comprising an rna guide targeting pdcd1 and uses thereof | |
| WO2023122433A1 (en) | Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha) | |
| CN117897485A (zh) | 包括靶向羟基酸氧化酶1(hao1)的rna向导的基因编辑系统和其用途 | |
| WO2023081377A2 (en) | Compositions comprising an rna guide targeting ciita and uses thereof | |
| HK40109011A (zh) | 包括靶向羟基酸氧化酶1(hao1)的rna向导的基因编辑系统和其用途 | |
| WO2023137451A1 (en) | Compositions comprising an rna guide targeting cd38 and uses thereof | |
| WO2025212120A1 (en) | Chemical modifications of guide rnas for crispr nucleases | |
| US20230416732A1 (en) | Compositions comprising an rna guide targeting bcl11a and uses thereof | |
| US20240026351A1 (en) | Compositions comprising an rna guide targeting trac and uses thereof | |
| CN117813382A (zh) | 包括靶向stathmin 2(stmn2)的rna向导的基因编辑系统和其用途 | |
| WO2025006563A1 (en) | Gene editing systems targeting pcsk9 and uses thereof | |
| WO2025049900A1 (en) | Crispr nuclease polypeptides and gene editing systems comprising such | |
| EP4627083A1 (en) | Reverse transcriptase-mediated genetic editing of transthyretin (ttr) and uses thereof | |
| WO2025171210A1 (en) | Compositions and methods for gene editing via homology-mediated end joining | |
| AU2024333717A9 (en) | Reverse transcription-mediated gene editing systems and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |